Brousse C
Service de rhumatologie, hôpital Foch, 40, rue Worth, 92150, Suresnes, France.
Rev Med Interne. 2003 Feb;24(2):123-6. doi: 10.1016/s0248-8663(02)00022-x.
TNFalpha inhibitors etanercept and infliximab, are a new and very exciting drugs. Etanercept is administered subcutaneously, and infliximab by intravenous perfusions.
They are indicated in severely rheumatoid arthritis resistant to treatment with methotrexate, and in Crohn's disease refractory to immunosuppressive agents. Their safety profile is good, but the risk of infections is increased.
Their indication in other inflammatory diseases need further studies.
肿瘤坏死因子α抑制剂依那西普和英夫利昔单抗是新型且令人兴奋的药物。依那西普通过皮下注射给药，英夫利昔单抗通过静脉灌注给药。
它们适用于对甲氨蝶呤治疗耐药的重度类风湿性关节炎以及对免疫抑制剂难治的克罗恩病。它们的安全性良好，但感染风险增加。
它们在其他炎症性疾病中的应用需要进一步研究。
